KaydedilenlerDerginizi ekleyin

Dergiler / Haydarpaşa Numune Medical Journal / 2022 / Cilt: 62 - Sayı: 2

Analysis of Isocitrate Dehydrogenase 1 Mutation and 10q23/ PTEN Alterations in Turkish Glioblastoma Patients

Ceren SÜMER
Figen CELEP EYÜPOĞLU
Havvanur TURGUTALP
Sayfa
200–205
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Discussion and Conclusion: Understanding the prevalence of IDH1 mutations and 10q23/PTEN alterations may have importance in terms of the diagnosis, prognosis, and treatment of GBM patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: The object of this study is to identify the frequency isocitrate dehydrogenase 1 gene (IDH1) mutations and 10q23/PTEN locus alterations in Turkish patients with glioblastoma multiforme (GBM).
📊
Temel Bulgular & Veri:Methods: For this purpose, DNAs obtained from paraffin-embedded archival materials belong to 54 cases diagnosed as GBM were applied direct sequencing.
💡
Sonuç & Katkı:Discussion and Conclusion: Understanding the prevalence of IDH1 mutations and 10q23/PTEN alterations may have importance in terms of the diagnosis, prognosis, and treatment of GBM patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: The object of this study is to identify the frequency isocitrate dehydrogenase 1 gene (IDH1) mutations and 10q23/PTEN locus alterations in Turkish patients with glioblastoma multiforme (GBM). Methods: For this purpose, DNAs obtained from paraffin-embedded archival materials belong to 54 cases diagnosed as GBM were applied direct sequencing. In addition, overall 25 cases and 10 non-neoplastic brain tissues which were used as controls were analyzed by fluorescent in situ hybridization (FISH). Results: We detected 5 heterozygous IDH1 c.395G>A mutations (9.3%) with wild-type arginine 132 replaced by histidine (R132H). Although there is no statistical significance between the age of the cases and IDH1 p.R132H mutation, the patients harboring the p.R132H mutation were younger (median age; 38) than patients without this mutation (median age; 52). The median survival time of the patients with this mutation was calculated at 7 months, while it was 5 months for the patients with no mutation; however, this finding was not statistically significant. According to our FISH results, we found a total of 16 10q23/PTEN alterations, of which 8 were hemizygous deletion (32%) and 8 were monosomy (32%). Discussion and Conclusion: Understanding the prevalence of IDH1 mutations and 10q23/PTEN alterations may have importance in terms of the diagnosis, prognosis, and treatment of GBM patients.

🔖

Bu Makaleye Atıf Yap

SÜMER, C., EYÜPOĞLU, F. C., TURGUTALP, H. (2022). Analysis of Isocitrate Dehydrogenase 1 Mutation and 10q23/ PTEN Alterations in Turkish Glioblastoma Patients. Haydarpaşa Numune Medical Journal, Cilt: 62 - Sayı: 2, 200–205. https://ajindex.com/articles/535857

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97– 109
  2. Oberheim Bush NA, Hervey-Jumper SL, Berger MS. Management of glioblastoma, present and future. World Neurosurg 2019;131:328–38
  3. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764–72
  4. Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol 2015;185:1820–33
  5. Asif S, Fatima R, Krc R, Bennett J, Raza S. Comparative proteogenomic characterization of glioblastoma. CNS Oncol 2019;8:CNS37
  6. Li QJ, Cai JQ, Liu CY. Evolving molecular genetics of glioblastoma. Chin Med J (Engl) 2016;129:464–71
  7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12
  8. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73
  9. Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol 2016;18:16–26
  10. Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: Alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010;102:932–41
  11. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, et al. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010;119:487–94
  12. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341–7
  13. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445–53. 14. Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. Semin Cancer Biol 2019;59:66–79
  14. Govender D, Chetty R. Gene of the month: PTEN. J Clin Pathol 2012;65:601–3
  15. M Gagné L, Boulay K, Topisirovic I, Huot MÉ, Mallette FA. Oncogenic activities of IDH1/2 mutations: From epigenetics to cellular signaling. Trends Cell Biol 2017;27:738–52
  16. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin C